Diabetes and cancer: Epidemiology and potential mechanisms

Diabetes and Vascular Disease Research

Volumn 11, Issue 6, 2014, Pages 390-394

  Joost, Hans Georg ^a,b  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

Cancer risk factors; cohort studies; confounders; hyperinsulinaemia; obesity

Indexed keywords

EXENDIN 4; INSULIN; METFORMIN; SITAGLIPTIN; ANTIDIABETIC AGENT;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; COLORECTAL CANCER; DIABETIC PATIENT; DISEASE ASSOCIATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN TREATMENT; LIVER CANCER; LIVER CELL CARCINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS CANCER; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLIC SYNDROME X; NEOPLASMS;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; NEOPLASMS; OBESITY;

EID: 84912030559     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114550813     Document Type: Review

References (44)

1. Marble A. Diabetes and cancer. N Engl J Med. 1934 ; 211: 339-349
2. Joslin EP, Lombard HL, Burrows RE, et al. Diabetes and cancer. N Engl J Med. 1959 ; 260: 486-488
3. Kessler. Cancer mortality among diabetics. J Natl Cancer Inst. 1970 ; 44: 673-686
4. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995 ; 273: 1605-1609
5. Chow WH, Gridley G, Nyrén O, et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst. 1995 ; 87: 930-931
6. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013 ; 104: 9-14
7. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010 ; 33: 1674-1685
8. Heidemann C, Boeing H, Pischon T, et al. Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: a prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort. Eur J Epidemiol. 2009 ; 24: 281-288
9. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011 ; 47: 1928-1937
10. Grote VA, Rohrmann S, Nieters A, et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia. 2011 ; 54: 3037-3046
11. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer. 2007 ; 120: 1993-1998
12. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011 ; 54: 25-31
13. Lawson DH, Gray JM, McKillop C, et al. Diabetes mellitus and primary hepatocellular carcinoma. Q J Med. 1986 ; 61: 945-955
14. Adami HO, Chow WH, Nyrén O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996 ; 88: 1472-1477
15. Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012 ; 130: 1639-1648
16. Borena W, Strohmaier S, Lukanova A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer. 2012 ; 131: 193-200
17. Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004 ; 127: S97-103
18. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010 ; 51: 1820-1832
19. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004 ; 126: 460-468
20. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005 ; 97: 1679-1687
21. Larsson SC, Giovannucci E, Wolk A. Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care. 2005 ; 28: 1805-1807
22. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006 ; 98: 920-931
23. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004 ; 4: 579-591
24. Cannata D, Fierz Y, Vijayakumar A, et al. Type 2 diabetes and cancer: what is the connection?. Mt Sinai J Med. 2010 ; 77: 197-213
25. Will JC, Galuska DA, Vinicor F, et al. Colorectal cancer: another complication of diabetes mellitus?. Am J Epidemiol. 1998 ; 147: 816-825
26. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007 ; 121: 856-862
27. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2004 ; 111: 762-771
28. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006 ; 15: 2056-2062
29. Evans JMM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005 ; 330: 1304-1305
30. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009 ; 32: 1620-1625
31. Landman GWD, Kleefstra N, van Hateren KJJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010 ; 33: 322-326
32. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 2012 ; 55: 2593-2603
33. Singh S, Singh H, Singh PP, et al. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2013; 22: 2258-2268.. :
34. Dideriksen L, Jorgensen L, Drejer K. Carcinogenic effect of the human insulin analogue B10 Asp in female rats (Abstract). Diabetologia. 1992 ; 35: A3
35. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009 ; 52: 1732-1744
36. Ehninger G, Schmidt AH. Putting insulin glargine and malignancies into perspective. Oncologist. 2009 ; 14: 1169-1174
37. Ljung R, Talbäck M, Haglund B, et al. Insulin glargine use and short-term incidence of breast cancer - a four-year population-based observation. Acta Oncol. 2012 ; 51: 400-402
38. Rendell M, Akturk HK, Tella SH. Glargine safety, diabetes and cancer. Expert Opin Drug Saf. 2013 ; 12: 247-263
39. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009 ; 52: 1971-1973
40. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009 ; 52: 2499-2506
41. Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 ; 367: 319-328
42. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011 ; 141: 150-156
43. Romley JA, Goldman DP, Solomon M, et al. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther. 2012 ; 14: 904-911
44. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012 ; 98: 271-284